Cutaneous & Abdominal Attacks

Share / Send / Save

Reduce and relieve HAE attack symptoms with FIRAZYR

FIRAZYR is used to treat acute HAE attacks in adults 18 years of age and older.

  • FIRAZYR was studied in 3 controlled clinical trials1

Across all 3 clinical trials, the median time to 50% reduction in symptoms for patients treated with FIRAZYR ranged from 2.0 to 2.3 hours.1

  • In FAST-3 (Trial 1), the median time to 50% symptom reduction for patients with cutaneous and abdominal attacks was 2.0 hours with FIRAZYR vs 19.8 hours with placebo (P<0.001)1
Graph displaying how patients experienced faster relief with FIRAZYR® (icatibant injection) vs placebo as demonstrated in Fast-3 (Trial 1)
  • Thirty percent of patients with cutaneous or abdominal attacks reported a 50% reduction in attack symptoms 1 hour following FIRAZYR administration (P=0.0149)1,2

Almost complete symptom resolution in just 8 hours

In FAST-3 (Trial 1), FIRAZYR-treated patients experienced almost complete symptom resolution in 8 hours vs 36 hours with placebo (median time).1

FAST-3 (Trial 1) study design

Trial 1 was a randomized, placebo-controlled, double-blind, parallel-group study of 98 adult patients with a median age of 36 years. Patients who had developed moderate to severe cutaneous or abdominal or mild to moderate laryngeal attacks of HAE were randomized to receive either FIRAZYR 30 mg or placebo by subcutaneous injection. Patients with severe laryngeal attacks of HAE received open-label FIRAZYR 30 mg. The primary endpoint was assessed using a 3-item composite visual analog score (VAS), comprising averaged assessments of skin swelling, skin pain and abdominal pain. Response was defined as at least a 50% reduction from the pretreatment composite 3-item VAS score. Other evaluated endpoints included time to almost complete symptom relief (VAS <10 mm) and rescue medication use.1

Other trials

In a second placebo-controlled trial and an active-controlled trial, a total of 26 and 35 patients, respectively, received FIRAZYR 30 mg for the treatment of an acute HAE attack.1